Trials / Completed
CompletedNCT02233504
Pilot Study to Assess Hematologic Response in Patients With Acute Myeloid Leukemia or High Risk Myelodysplastic Syndromes Undergoing Monotherapy With Exjade (Deferasirox)
- Status
- Completed
- Phase
- EARLY_Phase 1
- Study type
- Interventional
- Enrollment
- 25 (estimated)
- Sponsor
- Abramson Cancer Center at Penn Medicine · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this trial is to examine the hematologic response rate of Exjade® in patients with AML and high risk MDS and chronic iron overload from blood transfusions. Deferasirox has been developed as an iron-chelating agent, and unlike deferoxamine, a previously developed iron chelator, deferasirox has the advantage of oral administration.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Exjade® (deferasirox, ICL670) |
Timeline
- Start date
- 2014-08-01
- Primary completion
- 2017-10-01
- Completion
- 2017-10-02
- First posted
- 2014-09-08
- Last updated
- 2020-04-08
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT02233504. Inclusion in this directory is not an endorsement.